Director/PDMR Shareholding
(Thomson Reuters ONE) -
Summit Corporation plc
("Summit" or "the Company")
DIRECTOR'S TRANSFER OF SHARES
Oxford, UK, 18 May 2010, Summit (AIM: SUMM), a leading UK drug discovery company
with a portfolio of partnered drug programmes and a proprietary Seglin(TM)
technology platform, announces that on 17 May 2010 it was informed that
Professor Stephen Davies, Non-executive Director and co-founder of the Company,
transferred 7,658,748 Ordinary shares in the Company to HALB Nominees on 12 May
2010.
Following the transfer, Professor Davies beneficial shareholding remains
unchanged at 7,658,748 Ordinary shares, which represents 4.61 per cent. of the
issued share capital of Summit.
- END -
For more information, please contact:
Summit
Steven Lee, PhD
Richard Pye, PhD Tel: +44 (0)1235 443939
Singer Capital Markets (Nominated
Adviser)
Shaun Dobson / Claes Spång Tel: +44 (0)20 3205 7500
Peckwater PR
Tarquin Edwards Tel: +44 (0)7879 458 364
tarquin.edwards(at)peckwaterpr.co.uk
About Summit
Summit is an Oxford, UK based drug discovery company with a portfolio of partner
funded drug programmes and an innovative technology platform called Seglins(TM)
for the discovery of new medicines.
Summit's partnered drug programmes require no further investment from the
Company but have contractual, success-based milestones potentially worth in
excess of $160 million and sales royalties rising to a low teen percentage.
Partners include leading orphan drug specialist BioMarin Pharmaceuticals
(Duchenne Muscular Dystrophy programme) and the Wellcome Trust (C. difficile
programme).
Seglin(TM) technology
Seglin(TM) technology is using new chemistry to access biological drug targets
that cannot be exploited by conventional drug discovery approaches. Summit's
internal research is currently focussed in the high value therapy areas of type
II diabetes and infectious diseases and the Company will further exploit the
technology's wider potential through strategic alliances.
Summit is listed on the AIM market of the London Stock Exchange and trades under
the ticker symbol SUMM. Further information is available atwww.summitplc.com
[HUG#1416677]
Unternehmensinformation / Kurzprofil:
Datum: 18.05.2010 - 12:52 Uhr
Sprache: Deutsch
News-ID 21068
Anzahl Zeichen: 0
contact information:
Town:
Abingdon,
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Director/PDMR Shareholding"
steht unter der journalistisch-redaktionellen Verantwortung von
Summit Corporation PLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
